Derek McClure
Family · West Jefferson, NCNPI 1184738338
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,488 of the $13,968 with a category attached, or 67.9%. Amgen accounts for 70.8% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2024 at $9,364 and has fallen 96.7% since, to $306 in 2025. Among family clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $53.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$10K
- AbbVie$1K
- Corium, LLC$256
- Bausch Health US, LLC$245
- Sunovion Pharmaceuticals Inc.$239
- Novo Nordisk$215
- plus $2K from 32 others
What the payments were for
- Speaking & faculty fees$9,48868%
- Travel & lodging$5424%
- Food & beverage$3,93928%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 61 | $9,886 |
| AbbVie | 34 | $1,316 |
| Corium, LLC | 13 | $256 |
| Bausch Health US, LLC | 15 | $245 |
| Sunovion Pharmaceuticals Inc. | 14 | $239 |
| Novo Nordisk | 12 | $215 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $203 |
| Novartis | 13 | $198 |
| GSK | 7 | $119 |
| AstraZeneca | 8 | $117 |
| Phathom Pharmaceuticals, Inc. | 3 | $109 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $99 |
| Boehringer Ingelheim | 7 | $96 |
| Dexcom, Inc. | 3 | $91 |
| Pfizer | 4 | $80 |
| Bayer | 5 | $78 |
| Abbott | 4 | $73 |
| Lilly USA, LLC | 4 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Supernus Pharmaceuticals, Inc. | 3 | $47 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $46 |
| Insulet Corporation | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Alkermes, Inc. | 2 | $30 |
| Exact Sciences | 2 | $29 |
| Organon | 2 | $25 |
| Amarin Pharma, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
| OWP Pharmaceuticals, Inc. | 1 | $14 |
| Medtronic | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Nestle Healthcare Nutrition Inc. | 1 | $11 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,968 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 63 | $84,897 |
| Repatha SureclickEvolocumab | 91 | $72,471 |
| EliquisApixaban | 46 | $48,066 |
| VraylarCariprazine Hcl | 22 | $39,263 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 21 | $34,379 |
| BelbucaBuprenorphine Hcl | 34 | $25,155 |
| XareltoRivaroxaban | 27 | $23,037 |
| OzempicSemaglutide | 18 | $22,049 |
| GlyxambiEmpagliflozin/Linagliptin | 34 | $21,954 |
| FarxigaDapagliflozin Propanediol | 19 | $17,020 |
| LinzessLinaclotide | 13 | $15,061 |
| NovologInsulin Aspart | 23 | $6,437 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 13 | $2,933 |
| Fentanyl | 12 | $2,409 |
| Rosuvastatin Calcium | 270 | $2,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi | $96 | $106,85197 claims |
| AbbVieVraylar, Linzess, Synthroid | $1,316 | $55,70658 claims |
| PfizerEliquis | $80 | $48,06646 claims |
| Novo NordiskOzempic, Novolog | $215 | $28,48641 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $14 | $25,15534 claims |
| AstraZenecaFarxiga | $117 | $17,02019 claims |
| GSKShingrix | $119 | $2,93313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in West Jefferson
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.